onasemnogene abeparvovec-brve
onasemnogene abeparvovec-brve is listed in the FDA National Drug Code directory with 1 NDC code, marketed under brand name including ITVISMA. Available dosage form: injection, suspension.
Drug Details
- Generic Name
- onasemnogene abeparvovec-brve
- Brand Names
- ITVISMA
- Application Number
- BLA125856
- Sponsor
- Novartis Innovative Technologies Inc.
- NDC Codes
- 1
- Dosage Forms
- INJECTION, SUSPENSION
- Routes
- INTRATHECAL
- Active Ingredients
- ONASEMNOGENE ABEPARVOVEC
Indications and Usage
1 INDICATIONS AND USAGE ITVISMA is indicated for the treatment of spinal muscular atrophy (SMA) in adult and pediatric patients 2 years of age and older with confirmed mutation in survival motor neuron 1 (SMN1) gene. ITVISMA is an adeno-associated virus (AAV) vector-based gene therapy indicated for the treatment of spinal muscular atrophy (SMA) in adult and pediatric patients 2 years of age and older with confirmed mutation in SMN1 gene. ( 1 )